1,490 reports of this reaction
1.5% of all MIRABEGRON reports
#11 most reported adverse reaction
HYPERTENSION is the #11 most commonly reported adverse reaction for MIRABEGRON, manufactured by Astellas Pharma US, Inc.. There are 1,490 FDA adverse event reports linking MIRABEGRON to HYPERTENSION. This represents approximately 1.5% of all 99,871 adverse event reports for this drug.
MIRABEGRON has an overall safety score of 78 out of 100. Patients taking MIRABEGRON who experience hypertension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERTENSION is a less commonly reported adverse event for MIRABEGRON, but still significant enough to appear in the safety profile.
In addition to hypertension, the following adverse reactions have been reported for MIRABEGRON:
The following drugs have also been linked to hypertension in FDA adverse event reports:
HYPERTENSION has been reported as an adverse event in 1,490 FDA reports for MIRABEGRON. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERTENSION accounts for approximately 1.5% of all adverse event reports for MIRABEGRON, making it a notable side effect.
If you experience hypertension while taking MIRABEGRON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.